CSBio CSBio

X
[{"orgOrder":0,"company":"VarmX","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$36.6 million","upfrontCash":"Undisclosed","newsHeadline":"VarmX Raises \u20ac32 Million to Develop Innovative Reversal Agent for the Treatment of Bleeding in Patients on Oral Anticoagulants","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"VarmX"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.

            Lead Product(s): VMX-COO1

            Therapeutic Area: Hematology Product Name: VMX-COO1

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ysios Capital

            Deal Size: $36.6 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing July 08, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY